Difference between revisions of "Cutaneous T-cell lymphoma - null regimens"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 1: | Line 1: | ||
| + | <span id="BackToTop"></span> | ||
| + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | ||
| + | [[#top|Back to Top]] | ||
| + | </div> | ||
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the [[Cutaneous T-cell lymphoma|main CTCL page]] for current regimens. | The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the [[Cutaneous T-cell lymphoma|main CTCL page]] for current regimens. | ||
Revision as of 00:49, 4 August 2022
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main CTCL page for current regimens.
Relapsed or refractory
Placebo
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Prince et al. 2010 (L4389-11) | NR | Phase 3 (C) | Denileukin diftitox | Inferior PFS |
References
- L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains verified protocol PubMed NCT00050999